English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

[1] Folsom AR, Wu KK, Conlan MG. Fibrinogen and cardiovascular risk in the atherosclerosis risk in communities (ARIC) study. In: Ernst E et al., eds. Fibrinogen a New Cardiovascular Risk Factor 1992, pp. 124–9. Blackwell-MZV. [2] Barker et al. Relation of fetal and infant growth to plasma fibrinogen in adult live. Br Med J 1992; 304: 148–52. [3] Tsutsumi et al. Association between job characteristics and plasma fibrinogen in a normal working population. J Epidemiol Community Health 1999; 53: 348–54. [4] Lacoviello L et al. Genes encoding fibrinogen and cardiovascular risk. Hypertension 2001; 38: 1199–203. [5] Humphries SE et al. European Atherosclerosis Research Study; genotype at the fibrinogen locus (G-455-Abeta gene) is associated with differences in plasma fibrinogen levels in young men and women from different regions in Europe. Arterioscler Thromb Vasc Biol 1992; 15: 96–104. [6] Folsom AR et al. Beta fibrinogen gene-455G/A polymorphism and coronary heart disease incidence: ARIC Study. Ann Epidemiol 2001; 11: 166–70. [7] Nishiuma S et al. Genetic variation in the promotor region of the beta-fibrinogen gene is associated with ischemic stroke in a Japanese population. Blood Coagul Fibrinolysis 1998; 9: 373–9. [8] Gardemann A et al. Positive association of the beta fibrinogen H1/H2 gene variation to basal fibrinogen levels but not to coronary artery disease and myocardial infarction. Thromb Haemost, 1997; 77: 1120–6. [9] Droggen CJ et al. Interaction of coagulation defects and cardiovascular risk factors. Circulation 1998; 97: 1037–41. [10] Kohler HP et al. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med ; 342: 1792–801. [11] Bottinger C et al. HPA-1 and HPA-3 polymorphisms of platelet fibrinogen receptor and coronary artery disease and myocardial infarction. Thromb Haemost 2000; 83: 559–62. [12] Laule M et al. A1/A2 polymorphism of glycoprotein 3a and association with excess procedural risk for coronary catheter interventions; a case controlled study. Lancet 1999; 353: 708–12.

Further evidence that antithrombotic therapy is beneficial with streptokinase: improved early ST resolution and late patency with enoxaparin